Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27169489 | 1.00 | PGR (0.62) | PGRAR | |
| SCHEMBL15713151 | 0.93 | PGR (0.64) | PGRAR | |
| SCHEMBL1364705 | 0.92 | PGR (0.61) | PGRAR | |
| SCHEMBL1364469 | 0.92 | PGR (0.61) | PGRAR | |
| SCHEMBL1363087 | 0.92 | AR (0.74) | PGRAR | |
| SCHEMBL3431521 | 0.92 | AR (0.74) | PGRAR | |
| SCHEMBL1364459 | 0.91 | PGR (0.62) | PGRAR | |
| SCHEMBL3211575 | 0.91 | PGR (0.65) | PGRAR | |
| SCHEMBL1363454 | 0.91 | PGR (0.62) | PGRAR | |
| SCHEMBL12339406 | 0.91 | PGR (0.62) | PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-4334314-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-12-01 | — | — | US | disclosed |
| WO-2022235585-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-2260028-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2260028-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8629167-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629167-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8455525-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455525-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8268872-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8067448-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110224267-A1 | Selective androgen receptor modulators | Radius Health,Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | PGR 28/4885AR 9/4885 |
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, IGF1R | PGR 16/4885AR 1/4885 |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NR5A1, NCOA1, NR5A2 | PGR 79/4885AR 4/4885 |
| US-20110224267-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | PGR 28/4885AR 1/4885 |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | AR, SHBG, IGF1R | PGR 17/4885AR 1/4885 |
| US-20090253758-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | PGR 28/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.